Clinical Trial Update: A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

An active Phase 2 Roche-sponsored trial is evaluating combinations of an immune checkpoint inhibitor with Axitinib in untreated locally advanced unresectable or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Renal Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING